Rosalind Advisors Inc. Decreases Position in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Rosalind Advisors Inc. lowered its stake in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) by 95.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 127,220 shares of the company’s stock after selling 2,465,373 shares during the quarter. Clearside Biomedical accounts for about 0.1% of Rosalind Advisors Inc.’s portfolio, making the stock its 28th largest position. Rosalind Advisors Inc.’s holdings in Clearside Biomedical were worth $162,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of CLSD. SG Americas Securities LLC acquired a new position in Clearside Biomedical during the 1st quarter worth $49,000. XTX Topco Ltd boosted its stake in shares of Clearside Biomedical by 172.2% in the 2nd quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock valued at $71,000 after buying an additional 34,359 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Clearside Biomedical during the second quarter worth about $368,000. Renaissance Technologies LLC increased its stake in shares of Clearside Biomedical by 6.6% during the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock worth $757,000 after buying an additional 35,900 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Clearside Biomedical by 14.5% in the first quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock valued at $3,811,000 after acquiring an additional 314,480 shares in the last quarter. 18.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Clearside Biomedical

In related news, insider Ngai Hang Victor Chong bought 36,500 shares of the stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $1.00 per share, for a total transaction of $36,500.00. Following the purchase, the insider now owns 100,000 shares of the company’s stock, valued at $100,000. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 9.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. StockNews.com upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Friday, October 18th. Needham & Company LLC boosted their target price on shares of Clearside Biomedical from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Monday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Clearside Biomedical in a report on Tuesday, August 27th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Clearside Biomedical has a consensus rating of “Moderate Buy” and a consensus target price of $5.17.

Clearside Biomedical Price Performance

NASDAQ CLSD opened at $1.07 on Wednesday. Clearside Biomedical, Inc. has a 1 year low of $0.76 and a 1 year high of $2.12. The company has a market capitalization of $79.96 million, a PE ratio of -2.14 and a beta of 2.33. The company has a fifty day moving average of $1.18 and a two-hundred day moving average of $1.20.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.25 million. During the same quarter last year, the company earned ($0.15) EPS. On average, research analysts expect that Clearside Biomedical, Inc. will post -0.56 earnings per share for the current year.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.